Physician profile
Ryan L Yoder
NPI 1700994019
$9,777.31
in general payments reported to CMS, 2019-2025
45 companies · $2,102 in 2025
The $2,102 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $339 · 2021: $314 · 2022: $1,718 · 2023: $2,610 · 2024: $2,380 · 2025: $2,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,092.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,091.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,162.44 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Teva Pharmaceuticals USA, INC. | $876.06 | 2019-2025 | Austedo Xr, Austedo, Ajovy |
| Pfizer INC. | $821.46 | 2023-2025 | |
| Ucb, INC. | $659.54 | 2020-2025 | Briviact, Nayzilam, Rystiggo |
| Celgene Corporation | $617.00 | 2021-2025 | Zeposia |
| Sk Life Science, INC. | $565.51 | 2022-2025 | Xcopri |
| Neurelis, INC. | $493.98 | 2022-2025 | Valtoco |
| Argenx US, INC. | $442.26 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Novartis Pharmaceuticals Corporation | $323.78 | 2019-2025 | |
| Eisai INC. | $283.67 | 2022-2025 | |
| Genentech USA, INC. | $282.01 | 2022-2025 | Ocrevus Zunovo, Ocrevus |
| Acadia Pharmaceuticals INC | $277.44 | 2019-2025 | Nuplazid |
| Biohaven Pharmaceutical Holding Company Ltd. | $268.63 | 2022 | |
| Lundbeck LLC | $226.34 | 2020-2025 | Vyepti |
| Biogen, INC. | $215.02 | 2019-2024 | Vumerity, Plegridy, Tysabri |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $194.31 | 2019-2024 | Mavenclad |
| Lilly USA, LLC | $194.01 | 2021-2025 | Amyvid, Kisunla, Reyvow |
| Neurocrine Biosciences, INC. | $186.00 | 2022-2025 | Ingrezza, Ongentys |
| Tg Therapeutics, INC. | $159.79 | 2024-2025 | |
| Kyowa Kirin, INC. | $157.42 | 2019-2025 | Nourianz |
| Jazz Pharmaceuticals INC. | $135.57 | 2023-2024 | Epidiolex |
| Banner Life Sciences, LLC | $116.67 | 2022-2024 | |
| Amgen INC. | $115.64 | 2019-2023 | Aimovig |
| Tanabe Pharma America, INC. | $105.20 | 2023-2025 | Radicava |
| Astrazeneca Pharmaceuticals Lp | $97.54 | 2023-2025 | Andexxa, Wainua |
| Sunovion Pharmaceuticals INC. | $81.28 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $73.76 | 2021 | |
| Janssen Pharmaceuticals, INC | $66.60 | 2022-2023 | Xarelto, Ponvory |
| Avion Pharmaceuticals | $59.31 | 2022-2023 | Dhivy |
| Abbott Laboratories | $53.63 | 2019-2021 | |
| Horizon Therapeutics Plc | $50.45 | 2022-2023 | Uplizna |
| Sumitomo Pharma America, INC. | $48.17 | 2023-2024 | Aptiom |
| Takeda Pharmaceuticals U.S.A., INC. | $47.29 | 2024-2025 | Hyqvia |
| Cycle Pharmaceuticals INC | $45.06 | 2025 | Bafiertam, Tascenso Odt |
| Si-Bone, INC. | $40.53 | 2022 | |
| Alexion Pharmaceuticals, INC. | $34.68 | 2022-2023 | Soliris |
| Genzyme Corporation | $34.45 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $33.41 | 2020 | |
| Allergan, INC. | $27.18 | 2020 | |
| Aucta Pharmaceuticals, INC. | $26.77 | 2025 | Motpoly Xr |
| Catalyst Pharmaceuticals, INC. | $21.02 | 2023 | Fycompa |
| Adamas Pharmaceuticals, INC. | $17.78 | 2020 | |
| Amneal Pharmaceuticals LLC | $14.41 | 2023 | Rytary |
| Strongbridge US INC. | $12.23 | 2019 | |
| Supernus Pharmaceuticals, INC. | $12.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Yoder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.